Janux Therapeutics (JANX) FCF Margin (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of FCF Margin data on file, last reported at 337.8% in Q1 2026.

• On a quarterly basis, FCF Margin changed N/A year-over-year to 337.8% in Q1 2026; TTM through Mar 2026 was 565.33%, a 7168.0% decrease from a year earlier, with the FY2025 full-year figure at 819.59%, down 40224.0% from the prior year.
• FCF Margin for Q1 2026 stood at 337.8%, down from 129.49% in the prior quarter.
• Over the last five years, FCF Margin for JANX reached as high as 113.7% in Q2 2024 and fell as low as 1495.93% in Q2 2023.
• Historically, FCF Margin has averaged 577.74% across 5 years, with a median of 451.25% in 2024.
• Across the five-year window, FCF Margin slumped 221398 bps in 2022 and surged 138223 bps in 2024, its largest moves.
• Year by year, FCF Margin stood at 429.74% in 2022, then climbed by 2 bps to 423.24% in 2023, then decreased by 7 bps to 451.25% in 2024, then surged by 71 bps to 129.49% in 2025, then sank by 161 bps to 337.8% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 337.8% in Q1 2026, 129.49% in Q3 2025, and 451.25% in Q3 2024.